PLC continues to support the Regulatory filings and the Clinical Trial operations for ARS Pharmaceuticals as they successfully advance the development of ARS-1. ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine
PLC’s continued Regulatory support of Intravail® and its technology has assisted in the advancement of ARS-1 and its product development. Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals’ Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure to Epinephrine Injectors / 4 May 2020 / 0 Comments — ARS Pharmaceuticals’ lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has
PLC’s continued support of Neurelis in regulatory filings and clinical trial development, site management, data management for multiple successful trials and new product development results in approval and commercial availability of Valtoco®. Neurelis Announces Commercial Availability- Valtoco® (Diazepam Nasal Spray) for Seizure Cluster Rescue — VALTOCO is the first and only nasal spray treatment for